IIT RESEARCH INSTITUTE
- CHICAGO, IL 60616-3717
- iitri.org (company website, opens in a new tab)
- Corporate Entity (Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $5.4M
- Awards on record
- 4
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
IIT RESEARCH INSTITUTE has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About IIT RESEARCH INSTITUTE
- Headquarters
- CHICAGO, IL 60616-3717
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIDGBUFQYMKWB5
- CAGE03889
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $5.4M
- Awards on record
- 4
- Top funding agencies
- National Institutes of Health
Awards
75N91022C00010
Recompete < 6 mo: Potential end Mar 31, 2027 (4 months away)PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $3.5M
- Period of performance
- Apr 1, 2022 – Mar 31, 2027
75N91018F00005
Completed: Period of performance ended Jul 25, 2025IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF…
Department of Health and Human Services · National Institutes of Health
- Obligated
- $2M
- Period of performance
- Sep 17, 2018 – Jul 25, 2025
HHSN261201600015I-HHSN26100003
Completed: Period of performance ended Sep 30, 2022IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $626.3K
- Period of performance
- Sep 6, 2017 – Sep 30, 2022
75A50118F33002
Completed: Period of performance ended Sep 30, 2021IGF::OT::IGF
Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response
- Obligated
- $2.4M
- Period of performance
- Sep 24, 2018 – Sep 30, 2021
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N91022C00010 PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | Department of Health and Human Services · National Institutes of Health | 541715 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $3.5M | Apr 1, 2022 – Mar 31, 2027 | Recompete < 6 mo: Potential end Mar 31, 2027 (4 months away)AI brief for award 75N91022C00010Bid team for the recompete of award 75N91022C00010 |
75N91018F00005 under HHSN261201500024I IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF… | Department of Health and Human Services · National Institutes of Health | 541711 · R499SUPPORT- PROFESSIONAL: OTHER | $2M | Sep 17, 2018 – Jul 25, 2025 | Completed: Period of performance ended Jul 25, 2025 |
HHSN261201600015I-HHSN26100003 under HHSN261201600015I IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS | Department of Health and Human Services · National Institutes of Health | 541690 · R499SUPPORT- PROFESSIONAL: OTHER | $626.3K | Sep 6, 2017 – Sep 30, 2022 | Completed: Period of performance ended Sep 30, 2022 |
75A50118F33002 under HHSO100201700014I IGF::OT::IGF | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | 541711 · AN13HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT | $2.4M | Sep 24, 2018 – Sep 30, 2021 | Completed: Period of performance ended Sep 30, 2021 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
Primes it has worked under
- DYNPORT VACCINE COMPANY LLC
UEI LXNEGTYDR755
$2.2M
Subcontractor to this prime · 1 sub-award · latest Jun 5, 2024
- Department of the Army
- “SERVICES”
- LEIDOS BIOMEDICAL RESEARCH INC
UEI HV8BH9BPG8Y9
$932.3K
Subcontractor to this prime · 1 sub-award · latest Jan 12, 2026
- National Institutes of Health
- “RRV-SC M7 SUBC”
Subcontractors it has used
No reported sub-awards as a prime contractor.
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · as of Nov 9, 2026 · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
No SBIR/STTR awards on record
Source: SBIR.gov award records (opens in a new tab) · sync date not recorded
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
No active exclusion on record (checked Nov 14, 2026).
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 14, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)Primary
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Small business under this code’s size standard
SAM.gov reports this entity as small under 1 of 2 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with IIT RESEARCH INSTITUTE?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
